ArticleMediators of inflammation2026
Shao Di Pa Ning Decoction Attenuates Neuroinflammation in Parkinson's Disease via PI3K/AKT Signaling Pathway.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shao Di Pa Ning Decoction Attenuates Neuroinflammation in Parkinson's Disease via PI3K/AKT Signaling Pathway.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundParkinson's disease (PD) is a neurodegenerative disorder with limited therapeutic options. Shao Di Pa Ning Decoction (SDPND), a traditional Chinese medicine (TCM) compound formula for PD, has demonstrated therapeutic efficacy, but its underlying mechanisms remain unclear. PURPOSE: This research aims to systematically investigate the mechanisms of SDPND, focusing on its anti-inflammatory effects and related pathways in PD.
methodsThe bioactive components of SDPND were first characterized to establish its material basis. Subsequently, A53T mice were administered SDPND to evaluate therapeutic improvements in motor dysfunction and neuroinflammatory responses, followed by transcriptomic profiling to identify potential pathways. Network pharmacology analysis was employed to validate biological pathways associated with these therapeutic effects. Molecular docking was used to study binding interactions between components and inflammatory, thereby offering mechanistic insights, with western blotting ultimately confirming the modulation of PI3K/AKT pathway activity.
resultsChemical composition analysis revealed 91 compounds. SDPND alleviated motor deficits and mitigated neuroinflammatory responses in A53T mice. Transcriptomic profiling revealed significant downregulation of the PI3K/AKT pathway. Network pharmacology analyses independently reaffirmed the enrichment of PI3K/AKT signaling as a pivotal hub. Molecular docking demonstrated robust binding affinities between bioactive components and core targets within the PI3K/AKT pathway, while western blotting analysis confirmed SDPND mediated suppression of PI3K/AKT phosphorylation, further validating pathway inhibition as a key mechanistic driver.
conclusionOur findings first revealed a novel anti-neuroinflammatory mechanism of SDPND via PI3K/AKT pathway suppression, which underlies its efficacy in mitigating PD symptoms. This discovery provides a robust theoretical foundation and pinpoints a strategic target for refining clinical PD therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.